DBVT

Dbv Technologies S A

• TipRanks·09/30 12:55

  DBV Technologies: Viaskin Peanut’s Strong Pediatric Prospects and Unchanged $45 Price Target Support Buy Rating

• Benzinga·09/30 07:43

  Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review

• NASDAQ·09/30 05:20

  DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children

• NASDAQ·09/30 03:24

  DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy

• TipRanks·09/29 22:35

  DBV Technologies submits BLA to FDA for Viaskin Peanut Patch

• TipRanks·09/22 09:50

  Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and TransMedics Group (TMDX)

• Seeking Alpha·08/24 19:03

  Artisan International Small-Mid Fund Q2 2026 Portfolio Review

• TipRanks·07/30 21:45

  DBV Technologies announces sale of $50M of ADSs through ATM program

• Seeking Alpha·07/26 12:23

  DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap

• Seeking Alpha·07/23 20:46

  DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside

• TipRanks·07/22 12:30

  Fourteen new option listings and one option delisting on July 22nd

• TipRanks·07/17 21:05

  DBV Technologies announces $150M at-the-market offering

• TipRanks·07/17 14:20

  Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kalaris Therapeutics (KLRS)

• TipRanks·07/17 12:30

  Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)

• TipRanks·07/17 12:25

  Cantor Fitzgerald Keeps Their Buy Rating on DBV Technologies SA – American (DBVT)